UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
SCHEDULE 13D
(Rule 13d-101)
 
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED
PURSUANT TO § 240.13d-2(a)
 
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)*
 
Supernus Pharmaceuticals, Inc.
 (Name of Issuer)
 
Common Stock, par value $0.001 per share
 (Title of Class of Securities)
 
868459108
(CUSIP Number)
 
Michael R. Murphy
Discovery Group I, LLC
191 North Wacker Drive
Suite 1685
Chicago, Illinois 60606
Telephone Number: (312) 265-9600
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
 
April 13, 2015
(Date of Event which Requires Filing of this Statement)
 
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o
 
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
 

 

 
CUSIP No. 868459108
 
 
1.
Names of Reporting Persons.
Discovery Equity Partners, L.P.
 
 
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
     
   
(a)
 o
   
(b)
 o
 
 
3.
SEC Use Only
 
 
4.
Source of Funds (See Instructions)
WC
 
 
5.
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   o
 
 
6.
Citizenship or Place of Organization
Illinois
 
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
7.
Sole Voting Power
None.
 
8.
Shared Voting Power
2,291,779
 
9.
Sole Dispositive Power
None.
 
10.
Shared Dispositive Power
2,291,779
 
 
11.
Aggregate Amount Beneficially Owned by Each Reporting Person
2,291,779
 
 
12.
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o
 
 
13.
Percent of Class Represented by Amount in Row (11)
4.9%
 
 
 
14.
Type of Reporting Person (See Instructions)
PN
 
 
 

 

 
 
CUSIP No. 868459108
 
 
1.
Names of Reporting Persons.
Discovery Group I, LLC
 
 
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
     
   
(a)
 o
   
(b)
 o
 
 
3.
SEC Use Only
 
 
4.
Source of Funds (See Instructions)
AF
 
 
5.
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   o
 
 
6.
Citizenship or Place of Organization
Delaware
 
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
7.
Sole Voting Power
None.
 
8.
Shared Voting Power
2,291,779
 
9.
Sole Dispositive Power
None.
 
10.
Shared Dispositive Power
2,291,779
 
 
11.
Aggregate Amount Beneficially Owned by Each Reporting Person
2,291,779
 
 
12.
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o
 
 
13.
Percent of Class Represented by Amount in Row (11)
4.9%
 
 
14.
Type of Reporting Person (See Instructions)
IA
 
 
 

 

 
CUSIP No. 868459108
 
 
1.
Names of Reporting Persons.
Daniel J. Donoghue
 
 
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
     
   
(a)
 o
   
(b)
 o
 
 
3.
SEC Use Only
 
 
4.
Source of Funds (See Instructions)
AF
 
 
5.
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   o
 
 
6.
Citizenship or Place of Organization
United States of America
 
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
7.
Sole Voting Power
None.
 
8.
Shared Voting Power
2,291,779
 
9.
Sole Dispositive Power
None.
 
10.
Shared Dispositive Power
2,291,779
 
 
11.
Aggregate Amount Beneficially Owned by Each Reporting Person
2,291,779
 
 
12.
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o
 
 
13.
Percent of Class Represented by Amount in Row (11)
4.9%
 
 
14.
Type of Reporting Person (See Instructions)
IN
 
 
 

 

 
CUSIP No. 868459108
 
 
1.
Names of Reporting Persons.
Michael R. Murphy
 
 
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
     
   
(a)
 o
   
(b)
 o
 
 
3.
SEC Use Only
 
 
4.
Source of Funds (See Instructions)
AF
 
 
5.
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   o
 
 
6.
Citizenship or Place of Organization
United States of America
 
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
7.
Sole Voting Power
None.
 
8.
Shared Voting Power
2,291,779
 
9.
Sole Dispositive Power
None.
 
10.
Shared Dispositive Power
2,291,779
 
 
11.
Aggregate Amount Beneficially Owned by Each Reporting Person
2,291,779
 
 
12.
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o
 
 
13.
Percent of Class Represented by Amount in Row (11)
4.9%
 
 
14.
Type of Reporting Person (See Instructions)
IN
 
 
 

 

 
Item 1.
Security and Issuer
 
 
This Amendment No. 2 to Schedule 13D (“Amendment No. 2”) relates to the Common Stock, par value $0.001 per share (the “Common Stock”), of Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), which has its principal executive offices at 1550 East Gude Drive, Rockville, Maryland 20850. This Amendment No. 2 amends and supplements, as set forth below, the information contained in items 1, 3, 5 and 6 of the Schedule 13D filed by the Reporting Persons with respect to the Company on May 14, 2014, as amended by that Amendment No. 1 thereto filed by the Reporting Persons with respect to the Company on September 11, 2014 (as so amended, the “Schedule 13D”). All capitalized terms used herein but not defined herein have the meanings set forth in the Schedule 13D. Except as amended by this Amendment No. 2, all information contained in the Schedule 13D is, after reasonable inquiry and to the best of the Reporting Persons’ knowledge and belief, complete and correct as of the date of this Amendment No. 2.
 
Item 3.
Source and Amount of Funds or Other Consideration
 
 
Item 3 of the Schedule 13D is hereby amended to read in its entirety as follows:
 
The total purchase price for the 2,291,779 shares of Common Stock beneficially owned by the Reporting Persons as of April 14, 2015 was approximately $19,715,625. The source of such funds was the assets of Discovery Equity Partners, including proceeds of margin loans under margin loan facilities maintained in the ordinary course of business by the Discovery Equity Partners with a broker on customary terms and conditions. Discovery Equity Partners is the legal owner of all of the Common Stock beneficially owned by Discovery Group and Messrs. Donoghue and Murphy.

Item 5.
Interest in Securities of the Issuer
 
 
Item 5 of the Schedule 13D is hereby amended to read in its entirety as follows:
 
The information concerning percentages of ownership set forth below is based on 46,779,242 shares of Common Stock reported outstanding as of March 23, 2015 in the Company’s Proxy Statement for its 2015 Annual Meeting of Stockholders as filed with the Securities and Exchange Commission on March 30, 2015.
 
Discovery Equity Partners beneficially owns 2,291,779 shares of Common Stock as of April 14, 2015, which represents 4.9% of the outstanding Common Stock.
 
Discovery Group beneficially owns 2,291,779 shares of Common Stock as of April 14, 2015, which represents 4.9% of the outstanding Common Stock.
 
Mr. Donoghue beneficially owns 2,291,779 shares of Common Stock as of April 14, 2015, which represents 4.9% of the outstanding Common Stock.
 
Mr. Murphy beneficially owns 2,291,779 shares of Common Stock as of April 14, 2015, which represents 4.9% of the outstanding Common Stock..
 
Discovery Group is the sole general partner of Discovery Equity Partners. Messrs. Donoghue and Murphy are the sole managing members of Discovery Group. As a consequence, Discovery Group and Messrs. Donoghue and Murphy may be deemed to share beneficial ownership of all of the shares of Common Stock owned by Discovery Equity Partners.
 
 
 

 

 
 
The transactions in Common Stock effected by the Reporting Persons during the past 60 days are set out in Exhibit 1 hereto.
 
The Reporting Persons ceased to be beneficial owners of more than five percent of the Common Stock on April 13, 2015.
 
No person other than Discovery Equity Partners is known to any Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any of the shares of Common Stock reported herein.
 
Item 6.
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
 
 
Item 6 of the Schedule 13D is hereby amended to read in its entirety as follows:
 
There are no contracts, arrangements, understandings or relationships (legal or otherwise) between or among any of the Reporting Persons and any other person with respect to any securities of the Company other than the governing documents of Discovery Group and Discovery Equity Partners, the margin loan facilities referred to under Item 3 above, the Joint Filing Agreement of the Reporting Persons with respect to the Schedule 13D that were included as exhibits thereto, the Joint Filing Agreement of the Reporting Persons with respect to this Amendment No. 2 included as Exhibit 2 to this Amendment No. 2, and the Powers of Attorney granted by Messrs. Donoghue and Murphy with respect to reports under Section 13 of the Securities Exchange Act of 1934, as amended, which Powers of Attorney are included as Exhibit 3 and Exhibit 4, respectively, to this Amendment No. 2.
 
Item 7.
Material to Be Filed as Exhibits
   
 
Exhibit 1:     List of transactions effected by the Reporting Persons in the Company’s Common Stock during the 60-day period preceding this filing.
   
 
Exhibit 2:     Joint Filing Agreement dated as of April 15, 2015, by and among Discovery Equity Partners; Discovery Group; Daniel J. Donoghue; and Michael R. Murphy.
   
 
Exhibit 3:     Power of Attorney of Daniel J. Donoghue, dated as of April 28, 2008.
   
 
Exhibit 4:     Power of Attorney of Michael R. Murphy, dated as of April 28, 2008.
 
 
 

 

 
Signature
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
April 15, 2015
 
Date
 
 
DISCOVERY GROUP I, LLC,
for itself and as general partner of
DISCOVERY EQUITY PARTNERS, L.P.
 
 
By: Michael R. Murphy*
 
Signature
 
 
 
Michael R. Murphy, Managing Member
 
Name/Title
   
   
 
Daniel J. Donoghue*
 
Signature
   
 
 
Daniel J. Donoghue
 
Name/Title
   
   
 
Michael R. Murphy*
 
Signature
   
 
 
Michael R. Murphy
 
Name/Title
   
   
 
      *By: /s/ Mark Buckley
 
Mark Buckley
Attorney-in-Fact for Daniel J. Donoghue
Attorney-in-Fact for Michael R. Murphy

 
 

 


Exhibit Index
 

Exhibit 1
 
List of transactions effected by the Reporting Persons in the Company’s Common Stock during the 60-day period preceding this filing.
     
Exhibit 2
 
Joint Filing Agreement dated as of April 15, 2015, by and among Discovery Equity Partners; Discovery Group; Daniel J. Donoghue; and Michael R. Murphy.
     
Exhibit 3
 
Power of Attorney of Daniel J. Donoghue, dated as of April 28, 2008.
     
Exhibit 4
 
Power of Attorney of Michael R. Murphy, dated as of April 28, 2008.
 
 

 

 



EXHIBIT 1
 
TRANSACTIONS DURING PAST 60 DAYS
 
The Reporting Persons engaged in the following transactions in shares of Common Stock of the Company during the past 60 days. Such transactions involved the sale of shares on the NASDAQ Global Market. The prices reported below reflect the weighted average sale price of the shares of Common Stock sold on the relevant date. The Reporting Persons hereby undertake to provide upon request to the SEC staff full information regarding the number of shares and prices at which each transaction was effected.

Date
 
Type
 
Price
     
Shares
3/12/2015
 
Sale
 
 $   11.3517
 
1
 
22000
3/13/2015
 
Sale
 
 $   11.5641
 
2
 
22000
3/16/2015
 
Sale
 
 $   11.5344
 
3
 
7384
3/17/2015
 
Sale
 
 $   11.1942
 
4
 
30455
3/18/2015
 
Sale
 
 $   11.2268
 
5
 
37762
3/19/2015
 
Sale
 
 $   11.3836
 
6
 
49400
3/20/2015
 
Sale
 
 $   11.4007
 
7
 
44676
3/23/2015
 
Sale
 
 $   11.4870
 
8
 
34182
3/24/2015
 
Sale
 
 $   11.6430
 
9
 
42021
3/25/2015
 
Sale
 
 $   11.2854
 
10
 
8395
3/26/2015
 
Sale
 
 $   11.2665
 
11
 
44150
3/27/2015
 
Sale
 
 $   11.7279
 
12
 
42000
3/30/2015
 
Sale
 
 $   11.8291
 
13
 
15697
3/31/2015
 
Sale
 
 $   12.0026
 
14
 
50896
4/1/2015
 
Sale
 
 $   12.4912
 
15
 
56000
4/2/2015
 
Sale
 
 $   12.4137
 
16
 
31500
4/6/2015
 
Sale
 
 $   12.3102
 
17
 
19100
4/7/2015
 
Sale
 
 $   12.4661
 
18
 
41702
4/8/2015
 
Sale
 
 $   12.5312
 
19
 
42775
4/9/2015
 
Sale
 
 $   12.4590
 
20
 
39827
4/10/2015
 
Sale
 
 $   12.7234
 
21
 
53101
4/13/2015
 
Sale
 
 $   13.0013
 
22
 
40400
4/14/2015
 
Sale
 
 $   13.2145
 
23
 
28387
 

1 This transaction was executed in multiple trades at prices ranging from $11.16 – 11.45.
2 This transaction was executed in multiple trades at prices ranging from $11.31 – 11.79.
3 This transaction was executed in multiple trades at prices ranging from $11.37 – 11.74.
4 This transaction was executed in multiple trades at prices ranging from $11.08 – 11.38.
5 This transaction was executed in multiple trades at prices ranging from $11.10 – 11.36.
6 This transaction was executed in multiple trades at prices ranging from $11.24 – 11.56.
7 This transaction was executed in multiple trades at prices ranging from $11.30 – 11.51.
8 This transaction was executed in multiple trades at prices ranging from $11.39 – 11.53.
9 This transaction was executed in multiple trades at prices ranging from $11.36 – 11.97.
10 This transaction was executed in multiple trades at prices ranging from $11.00 – 11.43.
11 This transaction was executed in multiple trades at prices ranging from $11.00 – 11.44.
12 This transaction was executed in multiple trades at prices ranging from $11.44 – 11.81.
13 This transaction was executed in multiple trades at prices ranging from $11.79 – 12.20.
14 This transaction was executed in multiple trades at prices ranging from $11.59 – 12.34.
15 This transaction was executed in multiple trades at prices ranging from $12.10 – 12.97.
16 This transaction was executed in multiple trades at prices ranging from $12.315 – 12.83.
17 This transaction was executed in multiple trades at prices ranging from $12.18 – 12.38.
18 This transaction was executed in multiple trades at prices ranging from $12.37 – 12.50.
19 This transaction was executed in multiple trades at prices ranging from $12.50 – 12.69.
20 This transaction was executed in multiple trades at prices ranging from $12.30 – 12.5050.
21 This transaction was executed in multiple trades at prices ranging from $12.50 – 12.87.
22 This transaction was executed in multiple trades at prices ranging from $12.80 – 13.14.
23 This transaction was executed in multiple trades at prices ranging from $13.10 – 13.32.
 
 

 




EXHIBIT 2
 
JOINT FILING AGREEMENT

The undersigned hereby agree to the joint filing of the Amendment No. 2 to Schedule 13D to which this Agreement is attached.
 
Dated: April 15, 2015
     
 
DISCOVERY GROUP I, LLC,
for itself and as general partner of
DISCOVERY EQUITY PARTNERS, L.P.
 
       
       
 
By
Michael R. Murphy*  
   
Michael R. Murphy
 
   
Managing Member
 
       
       
  Daniel J. Donoghue*  
 
Daniel J. Donoghue
 
     
     
  Michael R. Murphy*  
  Michael R. Murphy  
       
       
  *By:  /s/ Mark Buckley  
   
 Mark Buckley
 
   
 Attorney-in-Fact for Daniel J. Donoghue
 
   
 Attorney-in-Fact for Michael R. Murphy
 
 
 

 




EXHIBIT 3
 
POWER OF ATTORNEY
 

The undersigned, Daniel J. Donoghue, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursuant to Section 13 of the Securities Exchange Act of 1934 and the rules thereunder on Schedule 13D or 13G, any and all amendments to such reports, with all exhibits, and any other forms or documents as may be necessary in connection with the filing of such reports with the United States Securities and Exchange Commission and any stock exchange or similar authority, granting unto said attorney full power and authority to do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete, as fully as the undersigned might or could do in person.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact and agent.

IN WITNESS WHEREOF the undersigned has caused this Power of Attorney to be executed this 28th day of April, 2008.

 

  /s/ Daniel J. Donoghue  
  Daniel J. Donoghue  
   
STATE OF ILLINOIS
)
 
) SS.
COUNTY OF COOK
)
 

I, Kareema M. Cruz, a Notary Public in and for the County of Cook, State of Illinois, DO HEREBY CERTIFY that Daniel J. Donoghue, who is personally known to me to be the same person whose name is subscribed to the foregoing instrument, appeared before me this day in person and acknowledged that he signed and delivered the said instrument as his own free and voluntary act, for the uses and purposes therein set forth.

Given under my hand and notarial seal, this 28th day of April, 2008.

 

     
  /s/ Kareema M. Cruz  
  Notary Public  

 

 

 




EXHIBIT 4
 
POWER OF ATTORNEY
 

The undersigned, Michael R. Murphy, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursuant to Section 13 of the Securities Exchange Act of 1934 and the rules thereunder on Schedule 13D or 13G, any and all amendments to such reports, with all exhibits, and any other forms or documents as may be necessary in connection with the filing of such reports with the United States Securities and Exchange Commission and any stock exchange or similar authority, granting unto said attorney full power and authority to do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete, as fully as the undersigned might or could do in person.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact and agent.

IN WITNESS WHEREOF the undersigned has caused this Power of Attorney to be executed this 28th day of April, 2008.

     
  /s/ Michael R. Murphy  
 
Michael R. Murphy
 
   
STATE OF ILLINOIS
)
 
) SS.
COUNTY OF COOK
)
 

I, Kareema M. Cruz, a Notary Public in and for the County of Cook, State of Illinois, DO HEREBY CERTIFY that Michael R. Murphy, who is personally known to me to be the same person whose name is subscribed to the foregoing instrument, appeared before me this day in person and acknowledged that he signed and delivered the said instrument as his own free and voluntary act, for the uses and purposes therein set forth.

Given under my hand and notarial seal, this 28th day of April, 2008.

 

     
  /s/ Kareema M. Cruz  
  Notary Public  
 
 

 

Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Supernus Pharmaceuticals Charts.
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Supernus Pharmaceuticals Charts.